Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 14/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22535069 | 0.77 | FPR2 (0.60) | FPR2 | |
| SCHEMBL725086 | 0.76 | FPR2 (1.00) | FPR2 | |
| SCHEMBL9985465 | 0.76 | FPR2 (1.00) | FPR2 | |
| SCHEMBL9984791 | 0.76 | FPR2 (1.00) | FPR2ALDH1A1 | |
| SCHEMBL725486 | 0.76 | FPR2 (1.00) | FPR2ALDH1A1 | |
| SCHEMBL22535036 | 0.72 | FPR2 (0.58) | FPR2MAPTRXFP1ALDH1A1EPHX2 | |
| SCHEMBL728585 | 0.70 | FPR2 (1.00) | FPR2MAPTRXFP1EPHX2MEN1 | |
| SCHEMBL9985516 | 0.70 | FPR2 (1.00) | FPR2MAPTRXFP1EPHX2MEN1 | |
| SCHEMBL726818 | 0.70 | FPR2 (0.64) | FPR2MAPTRXFP1ALDH1A1EPHX2 | |
| SCHEMBL12040519 | 0.69 | FPR2 (1.00) | FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10434112-B2 | Use of agonists of formyl peptide receptor 2 for treating dermatological diseases | ALLERGAN, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20170216326-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN, INC. | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216326-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885MAPT 3480/4885RXFP1 222/4885 |
| US-10434112-B2 | Use of agonists of formyl peptide receptor 2 for treating dermatological diseases | FPR2, FPR1, FPR3 | FPR2 1/4885MAPT 3480/4885RXFP1 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.